Contents
Issue 154 • May 2025
In association with
In Depth
The GLP-1 drug shortage is over. What’s next for the compounders?
Big pharma faces headwinds in China as vaccine sales decline
How can pharma manage rising trial costs?
Can AI replace medical writers? Experts say not immediately
Saving shelved ultra-rare therapies through unorthodox funding
Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts?
Weight loss implants to increase compliance and cut admin burden for patients